Core Insights - Tango Therapeutics reported promising clinical data for vopimetostat (TNG462), indicating a median progression-free survival (mPFS) of 7.2 months in patients with second-line MTAP-del pancreatic cancer, supporting the initiation of a pivotal trial in 2026 [1][5] - The company secured $225 million in financing, extending its cash runway into 2028, which will support ongoing clinical studies and development plans [1][2] - The combination studies of vopimetostat with RAS(ON) inhibitors are progressing well, with initial data expected in 2026 [1][2] Clinical Development - Vopimetostat demonstrated a 49% overall response rate (ORR) and a mPFS of 9.1 months in a histology-selective cohort of difficult-to-treat cancers, providing evidence of its strong activity [1][5] - The ongoing combination study of vopimetostat with RAS(ON) inhibitors is well-tolerated, with initial data anticipated in 2026 [5] - TNG456, another candidate, received Orphan Drug Designation (ODD) for malignant glioma, which offers marketing exclusivity and incentives upon regulatory approval [4][5] Financial Performance - As of September 30, 2025, the company reported $152.8 million in cash and equivalents, bolstered by $212 million in net proceeds from a public offering, ensuring operational funding through 2028 [8] - Collaboration revenue increased significantly to $53.8 million for Q3 2025, compared to $11.6 million in Q3 2024, driven by the conclusion of a collaboration agreement with Gilead [9] - The net income for Q3 2025 was $15.9 million, a turnaround from a net loss of $29.2 million in the same period of 2024 [14] Upcoming Milestones - The company plans to initiate a pivotal study for vopimetostat in second-line pancreatic cancer in 2026, alongside updates from ongoing studies [2][6] - Initial safety and efficacy data from the combination trials of vopimetostat with RAS(ON) inhibitors are expected in 2026 [11][12] - The lung cancer cohort of the vopimetostat study is fully enrolled, with updates planned for 2026 [5][11]

Core Insights - Tango Therapeutics Inc. has reported data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers, indicating a promising efficacy profile [1] Efficacy Results Across Study Indications - As of September 1, 2025, 179 patients were enrolled across all cancer types, with 154 receiving active doses of 200 mg and above - The overall response rate (ORR) across cancer types was 27%, with a disease control rate (DCR) of 78% and a median progression-free survival (mPFS) of 6.4 months [2] Efficacy Results in Pancreatic Cancer Patients - Among 64 patients with pancreatic cancer, 39 received active doses, showing an ORR of 25% in second-line patients and 15% in all pancreatic cancer patients - The DCR for all pancreatic cancer patients was 71%, with mPFS of 7.2 months in second-line patients and 4.1 months in third-line and above patients [7] Development Strategy in Pancreatic Cancer - The company plans to initiate a global, randomized, pivotal study in 2026, enrolling approximately 300 patients with MTAP-deleted pancreatic cancer who have received one prior line of therapy, comparing vopimetostat to standard chemotherapy regimens [3][4] Enrollment in Lung Cancer - As of September 1, 2025, 41 patients with second-line or higher lung cancer were enrolled, with 12 receiving active doses; a safety and efficacy update is expected in 2026 [5] Financial Actions - Tango Therapeutics has priced an underwritten offering of 21.02 million shares and pre-funded warrants to purchase up to 3.23 million shares at $8.66, expecting gross proceeds of approximately $210 million [5] Price Action - TNGX stock experienced a decline of 14.78%, trading at $7.38 [6]